Keri L Fakata

Learn More
OBJECTIVE A panel of experts in pain medicine and public policy convened to examine root causes and risk factors for opioid-related poisoning deaths and to propose recommendations to reduce death rates. METHODS Panelists reviewed results from a search of PubMed and state and federal government sources to assess frequency, demographics, and risk factors(More)
OBJECTIVE To assess the safety and efficacy of adding intrathecal morphine to intrathecal ziconotide in patients treated with stable ziconotide doses. DESIGN Multicenter, open-label study with a 4-week morphine titration phase during which ziconotide was held constant and an extension phase during which dosing of either drug could vary. SETTING(More)
Intrathecal therapy is an established treatment option for patients with severe chronic pain who do not receive adequate relief from less invasive methods. Ziconotide is the only nonopioid analgesic approved by the U.S. Food and Drug Administration for intrathecal administration. Ziconotide is approved for monotherapy only, but combination intrathecal(More)
Pain produced by musculoskeletal disorders commonly misconceived as having mechanical etiology often is caused by inflammatory mechanisms. Simple analgesics (ie, those that lack anti-inflammatory action) often are used to treat musculoskeletal pain when an anti-inflammatory analgesic may be more effective for the painful condition. This review addresses the(More)
Nociceptive and neuropathic types of pain occur in rheumatologic conditions. Most clinicians are familiar with the former, but many are not aware of the prevalence of the latter. The literature reports numerous examples of the occurrence of rheumatologic neuropathic pain, but little has been published on its management. In this article, neuropathic and(More)
  • 1